Antitumoral use of cabazitaxel
DC CAFC
First Claim
Patent Images
1. A method for treating a patient with prostate cancer that has progressed during or after treatment with docetaxel, comprising administering to said patient a dose of 20 to 25 mg/m2 of cabazitaxel, or a hydrate or solvate thereof, in combination with a corticoid.
3 Assignments
Litigations
1 Petition
Accused Products
Abstract
The invention relates to a compound of formula:
which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.
28 Citations
30 Claims
- 1. A method for treating a patient with prostate cancer that has progressed during or after treatment with docetaxel, comprising administering to said patient a dose of 20 to 25 mg/m2 of cabazitaxel, or a hydrate or solvate thereof, in combination with a corticoid.
- 27. A method of increasing the survival of a patient with a castration resistant or hormone refractory, metastatic prostate cancer that has progressed during or after treatment with docetaxel, comprising administering a dose of 20 to 25 mg/m2 of cabazitaxel, or hydrate or solvate thereof, to the patient in combination with prednisone or prednisolone.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeSanofi Mature IP (Sanofi )
-
Original AssigneeAventis Pharma SA (Sanofi )
-
InventorsGupta, Sunil
-
Primary Examiner(s)Anderson, James D
-
Application NumberUS13/456,720Publication NumberTime in Patent Office985 DaysField of SearchUS Class Current514/449CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/164 of a carboxylic acid with a...A61K 31/337 having four-membered rings,...A61K 31/56 Compounds containing cyclop...A61K 31/573 substituted in position 21,...A61K 38/193 Colony stimulating factors ...A61K 45/06 Mixtures of active ingredie...A61P 13/08 of the prostateA61P 15/00 Drugs for genital or sexual...A61P 25/16 Anti-Parkinson drugsA61P 35/00 Antineoplastic agentsA61P 35/04 specific for metastasisA61P 43/00 Drugs for specific purposes...
